Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, nordic and turkish myeloma study groups

BRINGHEN, Sara;PALUMBO, Antonio
Last
2015-01-01

2015
133
4
372
380
www.karger.ch/journals/aha/aha_jh.htm
Anticoagulation; Heparin; Low-molecular-weight heparin; Multiple myeloma; Thalidomide; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide; Treatment Outcome; Turkey; Hematology; Medicine (all)
Beksac, Meral; Waage, Anders; Bringhen, Sara; Kristinsson, Sigurdur Y.; Sucak, Gülsan Türköz; Gimsing, Peter; Lupparelli, Giulia; Firatli-Tuʇlular, Tulin; Juliusson, Gunnar; Turesson, Ingemar; Palumbo, Antonio
File in questo prodotto:
File Dimensione Formato  
Acta Haematol. 2015 133(4) 372-80.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.02 MB
Formato Adobe PDF
1.02 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1527260
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact